Spire Wealth Management’s Traws Pharma TRAW Stock Holding History

Spire Wealth Management’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12	Closed	-$5K	–	3008
2021 Q1	$5K	Buy	+12	New	+$4.53K	﹤0.01%	2658

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Spire Wealth Management's TRAW Position: Q2 2021 in Review

Spire Wealth Management sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 12 shares — an estimated $5K sold.

Spire Wealth Management first reported a position in TRAW in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

Spire Wealth Management reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
Spire Wealth Management sold 12 Traws Pharma shares in Q2 2021, an estimated $5K.
Spire Wealth Management first reported a position in Traws Pharma in Q1 2021 and held it in 1 quarter.
Spire Wealth Management's Traws Pharma position peaked at $5K in Q1 2021.
25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.